Unión Europea - estonio - EMA (European Medicines Agency)

teva b.v. - zoledroonhape - osteoporosis; osteitis deformans; osteoporosis, postmenopausal - narkootikumid luuhaiguste raviks - treatment of osteoporosis: , in post-menopausal women;, in men; , at increased risk of fracture including those with a recent low-trauma hip fracture. treatment of osteoporosis associated with long-term systemic glucocorticoid therapy: , in post-menopausal women;, in men; , at increased risk of fracture. ravi paget tõbi, luu täiskasvanutel.

Estonia - estonio - Ravimiamet

pfizer - gripi koguviirus, inaktiveeritud - süstelahus - 100ml 1tk

Unión Europea - estonio - EMA (European Medicines Agency)

astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - vaktsiinid - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.

Unión Europea - estonio - EMA (European Medicines Agency)

ultragenyx germany gmbh - evinacumab - hüperkolesteroleemia - lipiidi modifitseerivad ained - evkeeza is indicated as an adjunct to diet and other low-density lipoprotein-cholesterol (ldl-c) lowering therapies for the treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolaemia (hofh).

Unión Europea - estonio - EMA (European Medicines Agency)

pfizer europe ma eeig - respiratory syncytial virus, subgroup a, stabilized prefusion f protein / respiratory syncytial virus, subgroup b, stabilized prefusion f protein - respiratoorsed süntsüütilised viirusinfektsioonid - vaktsiinid - abrysvo is indicated for:passive protection against lower respiratory tract disease caused by respiratory syncytial virus (rsv) in infants from birth through 6 months of age following maternal immunisation during pregnancy. vt lõigud 4. 2 ja 5. active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by rsv. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.

Unión Europea - estonio - EMA (European Medicines Agency)

pfizer europe ma eeig - neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid - meningiit, meningokokk - vaktsiinid - nimenrix on märgitud aktiivseks immuniseerimiseks invasiivse meningokoki haiguste põhjustatud neisseria meningitidis grupp a, c, 6 nädalaste isikute w-135 ja y.